Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers 'a major step' closer to river blindness vaccine
Blackfly
River blindness is spread by blackflies that breed in rivers.

Disease affects around 17 million people worldwide

Researchers have taken a major step towards developing the world's first vaccine against river blindness.

Scientists at the University of Edinburgh say that a vaccination would end a 30 year quest to beat the disease, which affects around 17 million people across the globe.

Over 90 per cent of cases of river blindness occur in west and central Africa.  The disease is caused by infection with the parasitic worm Onchocerca volvulus and is spread by blackflies that breed in rivers.

Around 10 per cent of those infected go on to develop eye conditions, one per cent become blind, and 70 per cent develop very severe skin diseases which can lead to social exclusion.  

Current control of river blindness relies on mass distribution of a drug called ivermectin, which has been successful in reducing incidence of the condition wherever it has been used. However, children under five - who comprise up to 20 per cent of the population in endemic regions - are excluded from the treatment.

Now, scientists from the University of Edinburgh's Division of Infection and Pathway Medicine have identified three potential vaccine compounds the could offer protection against the disease.

They hope to take at least one of these potential vaccines to safety trials, and to test its effectiveness by 2025.  Eventually they hope to administer a vaccine to children as part of national immunisation programmes.

Commenting on the study, lead researcher professor David W Taylor, said: "New knowledge of the way nematode parasites regulate people's immune responses has guided formulation of experimental vaccines.

"A vaccine for river blindness would compliment and augment existing treatment and significantly improve the prospects for eliminating this disease from Africa."

The research initiative - The Onchocerciasis Vaccine for Africa (TOVA) - was launched in response to the London Declaration on Neglected Tropical Diseases which called for tools to eliminate river blinds from Africa.

TOVA builds on over 30 years of research by Academics from Edinburgh and researchers in Africa, Europe, and the US and involves 15 organisations across five countries.

Image (C) Wikimedia commons

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com